Immune Therapies for Hematologic Disorders
Recently the treatment of hematological and solid malignancies has been revolutionized by the introduction of novel immunotherapeutic strategies. Patients suffering from malignancies that seemed to be untreatable now experience long-term disease control with novel immunotherapies such as immune check point inhibitors and T-cell redirected strategies (CAR T-cells, TCR transduced T cells, bispecific antibodies).
Although great advances have been made in applying immunotherapies and understanding their modes of action, persistent and new challenges are encountered in daily practice that need to be overcome. Patients show primary and acquired resistance discrepancy in clinical and radiological benefit as well as life- threatening adverse events. These challenges and obstacles can only be overcome in an integrative and multidisciplinary team. Thus, the EHA SWG aims to provide a platform combining patient care, research, outreach, training and education to foster clinical and translational studies with rapid transition into patient benefit.
Check out the report of the 2nd European CAR T-cell Meeting here
This SWG will set up a training network, cooperate with other disciplines to establish novel response and toxicity assessment, develop new strategies and foster research to better define primary and acquired resistance to immunotherapy, develop European guidelines on management of immunotherapy in hematological malignancies and foster academic-industrial cooperation.
Some of the objectives of the SWG are:
- Completion of European guidelines on management of immunotherapy in hematological disorders in collaboration with the EBMT planned.
- New criteria of evaluation of response to immunotherapy.
- Foster academic-industrial cooperation.
- Update on the EHA-Roadmap Immunotherapy in hematological malignancies.
Become a registered member of this Scientific Working Group: Apply here